ArticleInfectious diseases and therapy2026
Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017-2024.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) infection in adults causes lower respiratory tract disease (LRTD) encompassing lower respiratory tract infection (LRTI), and exacerbations of chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF), yet RSV testing rates among these patients, especially among outpatients, are not well documented. This study evaluated RSV and influenza testing practices among United States (U.S.) adults seen in outpatient settings with LRTI, COPD exacerbation, or CHF exacerbation.
methodsWe quantified RSV and influenza testing rates in a retrospective cohort of adults ≥ 18 years old seen in outpatient settings for LRTI, COPD exacerbations, or CHF exacerbations from August 2017 to March 2024 using Optum
resultsA total of 2,208,009 LRTI outpatient encounters, 396,891 COPD and 422,648 CHF exacerbation events from the Optum
conclusionDespite increases over time, RSV testing remains infrequent among U.S. adult outpatients. This is particularly true among adults with COPD or CHF exacerbations, where RSV should be part of the differential diagnosis. Infrequent testing may reflect lack of specific RSV treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.